ACE Technology Guidances

ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 04 Jun 2024
Last Updated on 04 Jun 2024
A- A+
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
  • Ruxolitinib 5 mg, 15 mg and 20 mg tablets for treating grades II to IV acute graft-versus-host disease (GVHD) in patients who have an inadequate response to corticosteroids.

    Funding status

    Ruxolitinib 5 mg, 15 mg and 20 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2024.

    MAF assistance does not apply to ruxolitinib for treating moderate to severe chronic GVHD in patients who have an inadequate response to corticosteroids.


    Ruxolitinib for treating graft-versus-host disease (Published 4 Jun 24) PES Ruxolitinib for treating graft-versus-host disease (Published 4 Jun 24)